From: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia
Biomarker | IM gland subtype | N0 of glands | N0 + ve glands | N0 − ve glands | Sensitivity | Specificity | PPV/ | AUROC |
---|---|---|---|---|---|---|---|---|
(95% CI)a | (95% CI)a | NPV | ||||||
CD10 | Â | Â | Â | Â | Â | Â | Â | Â |
All cohorts | Â | Â | Â | Â | Â | Â | Â | Â |
 | Complete | 123 | 112 | 11 | 91.1% | 97.8% | 98.2%/ | 0.944 |
 | Incomplete | 92 | 2 | 90 | (84.6–95.5%) | (92.4–99.7%) | 89.1% |  |
IM-GC | Â | Â | Â | Â | Â | Â | Â | Â |
 | Complete | 64 | 56 | 8 | 87.5% | 100.0% | 100.0%/ | 0.938 |
 |  |  |  |  | (76.9–94.5%) | (89.1–100.0%) | 80.0% |  |
 | Incomplete | 32 | 0 | 32 |  |  |  |  |
IM + GC |  |  |  |  |  |  |  |  |
 | Complete | 59 | 56 | 3 | 94.9% | 96.7% | 96.6%/ | 0.958 |
 | Incomplete | 60 | 2 | 58 | (85.9–98.9%) | (88.5–99.6%) | 95.1% |  |
Das1 | Â | Â | Â | Â | Â | Â | Â | Â |
All cohorts | Â | Â | Â | Â | Â | Â | Â | Â |
 | Complete | 127 | 11 | 116 | 29.2% | 91.3% | 71.8%/ | 0.603 |
 |  |  |  |  | (20.3–39.3%) | (85.0–95.6%) | 63.0% |  |
 | Incomplete | 96 | 28 | 68 |  |  |  |  |
IM-GC | Â | Â | Â | Â | Â | Â | Â | Â |
 | Complete | 60 | 1 | 59 | 28.6% | 98.3% | 85.7%/ | 0.635 |
 | Incomplete | 21 | 6 | 15 | (11.3–52.2%) | (91.1–100.0%) | 79.7% |  |
IM + GC |  |  |  |  |  |  |  |  |
 | Complete | 67 | 10 | 57 | 29.3% | 85.1% | 68.8%/ | 0.572 |
 | Incomplete | 75 | 22 | 53 | (19.4–40.1%) | (74.3–92.6%) | 51.8% |  |